01. Lifecore Biomedical（LFCR.O）业绩电话会：2025年Q2，公司营收3260万美元，同比增长8%，毛利润1110万美元，增加110万美元，净亏损660万美元。上半年营收增长5%，毛利润增加380万美元，净亏损2280万美元。完成2430万美元股票发行，增强流动性。公司增长战略目标为12%营收复合年增长率，EBITDA利润率超25%。业务渠道增长，特别是大型跨国公司业务，占渠道的30%以上。

海量资讯、精准解读，尽在新浪财经APP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.